Hong Kong Stock Movement
CLOUDBREAK-B fell 15.18%. Based on recent key news:
<ol>
<li>
On January 6, CLOUDBREAK's Guangzhou branch received a court notice for judicial preservation, affecting the stock price. The court implemented judicial preservation on CLOUDBREAK's Guangzhou bank account at the request of Cedar Wealth, involving an amount of approximately RMB 2.55 million. Source: Zhitong Finance
</li>
<li>
On January 5, CLOUDBREAK's cornerstone investors had their lock-up period lifted, putting pressure on the stock price. Fucheng Holdings Limited extended the lock-up period to July 2, with approximately 17.72 million shares being unlocked. Source: Zhitong Finance
</li>
<li>
On January 6, CLOUDBREAK successfully submitted a new drug clinical trial application, which failed to boost the stock price. ADS Therapeutics LLC submitted a clinical trial application for CBT-009 to the Chinese National Medical Products Administration. Source: Zhitong Finance. The industry faces legal risks, and capital outflow is evident.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Kelong Botai Biotech-B fell 1.77%. Based on recent news:
<ol>
<li>
On January 5, Kelong Botai Biotech-B announced that its core product, Lukanasatuzumab combined with Pembrolizumab, was approved for first-line treatment of non-small cell lung cancer by the National Medical Products Administration of China. This news boosted market confidence but failed to sustain the stock price increase.
</li>
<li>
On January 7, Kelong Botai Biotech-B terminated its subscription for RMB 980 million in structured deposits from Bank of China, adjusting its financial strategy. Although the company stated that this move would not have a significant adverse impact on its financial condition, the market reacted negatively, leading to a decline in the stock price.
</li>
<li>
On January 8, Kelong Botai Biotech-B recorded a large transaction, with the transaction price being 7.22% lower than the previous closing price, involving a total of HKD 863 million. This large transaction further intensified the downward pressure on the stock price. The pharmaceutical sector is overall active, with significant progress in innovative drug research and development.
</li>
</ol>
Innovent Biologics rose 0.39%. Based on recent key news:
<ol>
<li>
On January 5, Innovent Biologics added seven innovative products to the medical insurance catalog, driving up the stock price. Innovent's products performed well in the domestic market, especially the breakthrough progress of Ma Shidu Peptide in diabetes treatment, further enhancing market confidence. Source: Zhitong Finance
</li>
<li>
On January 6, Nomura Securities analyst Zhang Jialin maintained a &#34;Buy&#34; rating on Innovent Biologics, with a target price of HKD 105.80. The analyst is confident in the market potential of Innovent's GLP-1 therapy Ma Shidu Peptide, believing that its differentiated mechanism and pricing strategy will support the company's future growth. Source: Nomura Securities
</li>
<li>
On January 5, Daiwa Securities raised Innovent Biologics' target price to HKD 112, emphasizing its leading position in the biopharmaceutical sector. Daiwa Securities believes that Innovent Biologics will continue to benefit from growth potential in the innovative drug field by 2026. Source: Zhitong Finance. The pharmaceutical industry shows differentiated growth, driven by chronic diseases.
</li>
</ol>
Sihuan Pharmaceutical rose 0.36%. Based on recent key news:
<ol>
<li>
On January 6th, 3SBio recorded a large transaction with a transaction amount exceeding HKD 60.7 million, and the stock price slightly fell to HKD 25.96. This transaction indicates active market interest in the stock; despite the slight price decline, there was a net active buying of HKD 33.17 million, suggesting that investors are optimistic about its future performance. Source: Economic Information Daily
</li>
<li>
On January 8th, CMB International released a weekly report on the pharmaceutical industry, pointing out that the Hong Kong stock pharmaceutical sector performed well, with 3SBio recommended as a focus in the innovative drug field. The report believes that with the sales volume of newly included varieties in medical insurance increasing, the valuation of 3SBio has not yet fully reflected the value of its core major products, and the market has high expectations for its future growth. Source: Jinwu Financial News
</li>
<li>
On January 5th, Guoyuan Securities (Hong Kong) analysts maintained a buy rating on 3SBio, with a target price of HKD 32.76. Analysts unanimously believe that 3SBio is a strong buy, with an average target price of HKD 42.69, reflecting market confidence in its future growth. Source: Guoyuan Securities (Hong Kong) Pharmaceutical sector performs well, focus on innovative drugs.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
BeiGene rose 0.55%. Based on recent key news:
<ol>
<li>
On January 6th, BeiGene's Class 1 new drug, Tazemetostat, received conditional approval from the National Medical Products Administration for the treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma. This approval brings new market opportunities for the company, driving the stock price up. Source: Jinshi Data
</li>
<li>
On January 5th, the Hang Seng Pharmaceutical ETF surged 5.1%, with BeiGene benefiting as one of the holdings from the overall upward trend in the innovative drug sector. Source: Daily Economic News
</li>
<li>
On January 7th, BeiGene announced the grant of a total of 53,300 restricted stock units of American Depositary Shares to 155 grantees, demonstrating the company's confidence in future development and further boosting market sentiment. Source: Zhito Finance Innovative drug sector performs strongly, with significant capital inflow
</li>
</ol>

02592

CLOUDBREAK-B fell 15.18%; Kelun-B fell 1.77%, with a transaction amount reaching HKD 1.052 billion; Innovent Biologics rose 0.39%, with a transaction amount reaching HKD 745 million; 3SBio rose 0.36%, with a transaction amount reaching HKD 444 million; BeiGene rose 0.55%, with a market value reaching HKD 308 billion

Hong Kong Stock Movement: CLOUDBREAK-B fell 15.18%, facing a double blow to its stock price from judicial preservation and lifting of restrictions